Israeli scientists launch world-first clinical trial for experimental pancreatic cancer treatment
The Israeli-developed treatment uses RNA molecules to silence mutated KRAS genes and will be tested alongside standard therapy in patients with locally advanced disease
Assessment
A new clinical trial in Israel targets pancreatic cancer by using RNA molecules to disable mutated KRAS genes, a common driver of the disease. The treatment will be tested alongside standard therapy in patients whose cancer has not yet spread widely. Success could open a novel therapeutic pathway for one of the most lethal cancers, where treatment options are limited. The trial's early results will be closely watched by the oncology community.